Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immune pathways and complement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results